



2024/3/15

產業類別	電機
投資建議	買進 
收盤價	目標價
NT\$ 173.00	NT\$ 213.00

本次報告：法說會

交易資料

潛在報酬率 (%)	23.12
52 週還原收盤價區間 (NT\$)	90.90-174.00
市值 (NT\$百萬元)	87040
市值 (US\$百萬元)	2,763
流通在外股數 (百萬股)	503.00
董監持股 (%)	10.58
外資持股 (%)	14.19
投信持股 (%)	0.40
融資使用率 (%)	25.07

財務資料

	2023
股東權益 (NT\$百萬元)	15,754
ROA (%)	3.7
ROE (%)	10.99
淨負債比率 (%)	63.89

公司簡介

中興電工主要營運項目包括電力設備銷售、電力工程、空調機械設備與工程、停車場管理服務、精密機械設備及工程。公司近幾年致力於新能源事業，營運包括甲醇重組型燃料電池、引擎除碳機、微電網系統等。2022 年營收比重綠能 (太陽光電、氫能、供電設備) 66.5%、服務 (嘟嘟房、維運管理) 20%、其他 13.5%。

主要客戶：台電

主要競爭對手：

林其美 iris.lin@sinozac.com

中興電 (1513 TT)

海內外商機拓展持續


永豐觀點

國內重電設備持續取單，美國與日本市場有拓展商機的機會。

投資評價與建議


調升目標價：考量：(1) 國內重電設備公司取單持續增加，在手訂單能見度長，中長期重電營收有保障，另外美國與日本也有拓展商機的機會，(2) 為因應 RE100，用電大戶有購買綠電的需求，市場價格高於台電，若公司未來轉向售電予企業，將為後續公司於太陽能營收與獲利提升提供動能，(3) 嘟嘟房與敦南都更案是今年成長動能之一。中興電長期本益比 17-18 倍，其一次性不利因素影響已過，重電事業訂單能見度長，維持買進建議，目標價由 203 元 (23X 2024 EPS) 調升至 213 元 (21 X 2025EPS)。

近八季營收及 YoY 趨勢圖



資料來源：CMoney；永豐投顧研究處整理，Mar. 2024

近八季營業利益及毛利率趨勢圖



資料來源：CMoney；永豐投顧研究處整理，Mar. 2024

營運現況與分析

公司簡介：中興電工成立於 1962 年，主要營運項目包括電力設備銷售、電力工程、空調機械設備與工程、停車場管理服務、精密機械設備及工程。公司近幾年致力於新能源事業，營運包括甲醇重組型燃料電池、引擎除碳機、微電網系統等。2022 年營收比重綠能（太陽光電、氫能、供電設備）66.5%、服務（嘟嘟房、維運管理）20%、其他（都市更新、系統整合、精密加工）13.5%。

國內重電持續取單，美國與日本市場有拓展商機的機會：中興電重電事業 2023 年營收 120 億元，在手訂單 340 億元，2024 年將再取單 350 億元（原本預估 300 億元），主要是增加離島如澎湖與小離島岸場的訂單，公司能取得訂單，與公司的儲能 EPC 案場能力、工程能力、微電網與 GIS 能力有關。在產能方面，嘉義廠已於 1 月投產，將提升產能 15-20%，公司規劃將進一步擴增倉儲空間並增加人力，預計 4Q24 將可再提升 20% 產能。除了國內重電設備與工程訂單能見度長以外，公司與同業合作獲取美國 1,900 萬美元變壓器訂單，預期交期為 18 個月，由合作夥伴出小型變壓器，搭配公司的 GCB 與 CIO，目前變壓器已通過認證，出貨時間將落在明年，公司的 GCB 與 CIO 在認證當中。此案主要只出設備給美國的公司，美國公司的客戶為德州的電力公司。除了美國，日本對重電設備需求量也很大，公司出貨 84KV 與 72.5KV 的 GIS 部分組件至日本，此由中國的工廠出貨，2023 年金額已達 3 億元，預估今年將再成長 20%。

花蓮太陽能案場已終止進行，七股案場有提升獲利的空間：公司太陽能光電投資案，七股案場已開始營運，花蓮案場終止投資、土地將不再續租。七股案場已於 2021 年掛錶，該案場 216MW，年營收 15-16 億元，目前只賣電給台電，為因應 RE100，用電大戶有購買綠電的需求，市場價格高於台電，若公司未來轉向售電予企業，將為後續公司於太陽能營收與獲利提升提供動能。

嘟嘟房與敦南都更案是今年成長動能之一：公司發展氫能多年，2024 年將集中投資於台灣建立氫能示範點以利 2025 年國際業務推動，預計 2026 年後有明顯成長的機會。除此之外，嘟嘟房營收 2023 年 28 億元，疫後國內旅遊復甦，今年營收將顯著成長。另外敦南都更案有 22 億元營收待認列，預計今年將認列。

財務預估：預估 2024 年營收 261.57 億元（+18.12%YoY），營業利益 53.22 億元，稅後淨利 43.65 億元（+175.22%YoY），EPS 為 8.68 元。預估 2025 年營收 306.2 億元（17.06%YoY），營業利益 62.79 億元，稅後淨利 51.1 億元（+17.07%YoY），EPS 為 10.16 元。

附表一：當年度損益表

單位：百萬元	24Q1F	24Q2F	24Q3F	24Q4F	2024F
營業收入	6,050	6,285	6,807	7,015	26,157
營業毛利	1,754	1,851	2,092	2,118	7,815
營業利益	1,163	1,279	1,440	1,440	5,322
稅前淨利	1,208	1,324	1,485	1,488	5,505
稅後純益	958	1,050	1,177	1,180	4,365
稅後 EPS (元)	1.9	2.09	2.34	2.35	8.68
營收 QoQ 成長率	3.49	3.88	8.31	3.06	--
營收 YoY 成長率	3.58	27.51	23.16	20.00	18.12
毛利率	28.99	29.45	30.73	30.19	29.88
營益率	19.22	20.35	21.15	20.53	20.35
稅後純益率	15.83	16.71	17.29	16.82	16.69

資料來源：CMoney；永豐投顧研究處整理，Mar. 2024

附表二：五個年度損益表

單位：百萬元	2021	2022	2023	2024F	2025F
營業收入	18,027	18,547	22,145	26,157	30,620
%變動率	17.13	2.88	19.40	18.12	17.06
營業毛利	4,297	4,744	6,419	7,815	9,179
毛利率 (%)	23.84	25.58	28.99	29.88	29.98
營業淨利	2,677	2,851	4,386	5,322	6,279
稅前淨利	2,479	3,092	2,397	5,505	6,469
%變動率	37.59	24.74	-22.49	129.66	17.51
稅後純益	1,956	2,434	1,586	4,365	5,110
%變動率	28.07	24.44	-34.86	175.22	17.07
稅後 EPS * (元)	4.19	5.21	3.25	8.68	10.16
市調 EPS * (元)	3.81	4.67	3.56	8.26	--
PER (x)	41.29	33.21	53.23	19.93	17.03
PBR (x)	7.23	6.29	5.53	5.42	4.55
每股淨值 * (元)	23.92	27.51	31.31	31.89	38.05
每股股利 (元)	2.80	3.31	3.60	--	--
殖利率 (%)	6.69	5.05	3.09	--	--

* 以目前股本計算


資料來源：CMoney；永豐投顧研究處整理，Mar. 2024

營運基本資料


同業比較

代號	公司	投資建議	目前股價	市值(億)	稅後 EPS		PE		PB	
					2023	2024	2023	2024	2023	2024


近三年單月營收狀況




近三年單季營收 VS 毛利率趨勢圖




負債比率 VS 存貨周轉天數



歷史 PE 圖



歷史 PB 圖



臺北	永豐證券投資顧問股份有限公司 臺北市忠孝西路一段 80 號 14 樓 電話：(886-2) 2361-0868	永豐金證券股份有限公司 臺北市重慶南路一段 2 號 17 樓 電話：(886-2) 2311-4345
香港	永豐金證券(亞洲)有限公司 香港銅鑼灣新寧道 1 號 7 樓 電話：(852) 2586-8288	
上海	永豐金證券(亞洲)有限公司上海代表處 中國上海市浦東新區世紀大道 1528 號陸家嘴基金大廈 1903A-2 室 電話：(86-21) 6228-8220	
倫敦	永豐金證券(歐洲)有限公司 6 Lloyds Avenue, London EC3N 3AX, UK 電話：(44-20) 7614-9999	

責任聲明

本報告內容僅供參考，客戶應審慎考量本身之需求與投資風險，本公司恕不負任何法律責任，亦不作任何保證。本報告中之內容或有取材於本公司認可之來源，但並不保證其真實性或完整性；報告中所有資訊或預估，變更時本公司將不作預告，若資料內容有未盡完善之處，恕不負責。此外，非經本公司同意，不得將本報告加以複製或轉載。

110 年金管投顧新字第 024 號

SinoPac 投資評等

B：Buy 買進：未來 12 個月該股票表現將優於大盤
N：Neutral 中立：未來 12 個月該股票表現將與大盤一致
S：Sell 賣出：未來 12 個月該股票表現將落後大盤

Analyst Certification:

For each company mentioned in this research report, the respective analyst(s) who cover the company certifies (certify) that all of the views expressed in this research report accurately reflect his (their) personal views about any and all of the subject issuer(s) or securities. The analyst(s) also certifies (certify) that no part of her (their) compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

SinoPac Research Stock Rating System:

Buy: We think the stock will outperform the broader market over the next 12 months.

Neutral: We think the stock will perform in line with the broader market over the next 12 months.

Sell: We think the stock will underperform the market over the next 12 months.

Global Disclaimer:**Important Notice for UK Persons**

This Document may only be issued or passed on to any person in the United Kingdom if that person is of a kind described in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2001 or otherwise pursuant to exemptions to section 21 of the Financial Services and Markets Act 2000. In addition, no person who is an Authorized Person may issue or pass on this document, or otherwise promote SPSE, to any person in the United Kingdom other than by the rules of the Financial Conduct Authority (FCA) applicable to such Authorized Persons. This Document is confidential and is intended solely for the use of its recipient.

Important Disclosures for U.S. Persons

This research report was prepared by SinoPac Securities Corporation (SinoPac), a company authorized to engage in securities activities in Taiwan. SinoPac is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Auerbach Grayson & Company, 20 Wall West 55th Street, New York, NY 10019, a registered broker dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through SinoPac. Auerbach Grayson & Company accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of Auerbach Grayson & Company and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Ownership and Material Conflicts of Interest

Auerbach Grayson & Company or its affiliates does not 'beneficially own,' as determined in accordance with Section 13(d) of the Exchange Act, 1% or more of any of the equity securities mentioned in the report. Auerbach Grayson & Company, its affiliates and/or their respective officers, directors or employees may have interests, or long or short positions, and may at any time make purchases or sales as a principal or agent of the securities referred to herein. Auerbach Grayson & Company is not aware of any material conflict of interest as of the date of this publication.

Compensation and Investment Banking Activities

Auerbach Grayson & Company or any affiliate has not managed or co-managed a public offering of securities for the subject company in the past 12 months, nor received compensation for investment banking services from the subject company in the past 12 months, neither does it or any affiliate expect to receive, or intends to seek compensation for investment banking services from the subject company in the next 3 months.

Additional Disclosures

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither SinoPac nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

SinoPac may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of SinoPac.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by SinoPac with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of SinoPac and SinoPac accepts no liability whatsoever for the actions of third parties in this respect.

SinoPac Securities (Europe) Limited is regulated by the FCA